Akebia Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Akebia Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Akebia Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock
Investors are testing whether Akebia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Investors are testing whether Akebia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Akebia Therapeutics, Inc. Scheduled to Report Q4 and Full Year 2024 Financial Results on March 13, 2025
The story matters when it changes Akebia Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Investors are testing whether Akebia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest AKBA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Akebia Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →